BWM
AXDX

Baystate Wealth Management’s Accelerate Diagnostics AXDX Stock Holding History

Baystate Wealth Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$196 Buy
+50
New +$264 ﹤0.01% 1267

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $139M AUM
TWA
TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baystate Wealth Management's AXDX Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in Accelerate Diagnostics (AXDX) in Q4 2023: 50 shares worth $196. The stake represents ﹤0.01% of the portfolio and ranks #1267 among its holdings.

43 funds tracked by Wall St. Rank hold AXDX as of Q4 2023.

  • Baystate Wealth Management held 50 shares of Accelerate Diagnostics worth $196 as of Q4 2023.
  • Accelerate Diagnostics was a new Baystate Wealth Management position in Q4 2023.
  • Accelerate Diagnostics made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1267 holding.
  • 43 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.